Cargando…
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. We designed and validated a high-throughput sequencing method for minimal residual disea...
Autores principales: | Onecha, Esther, Linares, Maria, Rapado, Inmaculada, Ruiz-Heredia, Yanira, Martinez-Sanchez, Pilar, Cedena, Teresa, Pratcorona, Marta, Oteyza, Jaime Perez, Herrera, Pilar, Barragan, Eva, Montesinos, Pau, Vela, Jose Antonio Garcia, Magro, Elena, Anguita, Eduardo, Figuera, Angela, Riaza, Rosalia, Martinez-Barranco, Pilar, Sanchez-Vega, Beatriz, Nomdedeu, Josep, Gallardo, Miguel, Martinez-Lopez, Joaquin, Ayala, Rosa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355493/ https://www.ncbi.nlm.nih.gov/pubmed/30093399 http://dx.doi.org/10.3324/haematol.2018.194712 |
Ejemplares similares
-
Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse
por: Onecha, Esther, et al.
Publicado: (2020) -
P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)
por: Zamanillo, Irene, et al.
Publicado: (2023) -
Impact of IPSS-M implementation in real-life clinical practice
por: Zamanillo, Irene, et al.
Publicado: (2023) -
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
por: Jiménez-Ubieto, Ana, et al.
Publicado: (2023) -
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
por: Jiménez-Ubieto, Ana, et al.
Publicado: (2023)